AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28771093 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (edible cannabis lollipop with no active THC)
Number of subjects: 20
Study 25603725 — intervention group
Group type: EXPERIMENTAL
Intervention: Poractant alfa
Number of subjects: 30
Study 25603725 — intervention group
Group type: EXPERIMENTAL
Intervention: Beractant
Number of subjects: 30
Study 25603725 — intervention group
Group type: COMPARATOR
Intervention: Control group (preterm infants without RDS)
Number of subjects: 30
Study 23559412 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training with whole-body vibration
Number of subjects: 22
Study 23559412 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training without whole-body vibration
Number of subjects: 22
Study 23559412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 21150933 — intervention group
Group type: EXPERIMENTAL
Intervention: Office pulse pressure (PP)
Number of subjects: 4449
Study 21150933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory pulse pressure (PP)
Number of subjects: 4449
Study 21150933 — intervention group
Group type: EXPERIMENTAL
Intervention: Office and ambulatory pulse pressure (PP)
Number of subjects: 4449
Study 19634965 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline meaning/peace
Number of subjects: 583
Study 19634965 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in meaning/peace over 6 months
Number of subjects: 583
Study 19634965 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline faith
Number of subjects: 583
Study 19634965 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in meaning/peace
Number of subjects: 583
Study 19634965 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in faith
Number of subjects: 583
Study 19634965 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning/peace and faith interaction
Number of subjects: 583
Study 17936154 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3902 2.5 mg
Number of subjects: 181
Study 17936154 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3902 15 mg
Number of subjects: 181
Study 17936154 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3902 30 mg
Number of subjects: 181
Study 17936154 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3902 60 mg
Number of subjects: 181
Study 17936154 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3902 (all doses)
Number of subjects: 181
Study 17936154 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-3902 10 mg
Number of subjects: 181
Study 17936154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 15378139 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin daily plus usual therapy
Number of subjects: 205
Study 15378139 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy (control group)
Number of subjects: 205
Study 12003478 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative past experiences (unfavorable implications)
Number of subjects: 3
Study 12003478 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive past experiences (flattering implications)
Number of subjects: 3
Study 12003478 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem participants
Number of subjects: 3
Study 12003478 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-esteem participants
Number of subjects: 3
Study 12003478 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of rehearsal and ease of recall
Number of subjects: 3
Study 9652440 — intervention group
Group type: EXPERIMENTAL
Intervention: Isogenic hemolysin-deficient mutant (35000HP-RSM1)
Number of subjects: 0
Study 9652440 — intervention group
Group type: COMPARATOR
Intervention: Parent strain (35000HP)
Number of subjects: 0
Study 7808646 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients at risk for ARDS
Number of subjects: 24
Study 7808646 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 24
Study 2628706 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% metronidazole solution (MD)
Number of subjects: 12
Study 2628706 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (MDP)
Number of subjects: 12
Study 1104059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 1200 mg/day
Number of subjects: 20
Study 1104059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31915172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and/or fish oil supplementation for 5 years
Number of subjects: 25871
Study 31915172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D and/or fish oil supplementation)
Number of subjects: 25871
Study 31267113 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized 5' UTRs
Number of subjects: 280000
Study 31267113 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically modified RNA
Number of subjects: 280000
Study 31267113 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncated human 5' UTRs
Number of subjects: 280000
Study 31267113 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally occurring variants
Number of subjects: 280000
Study 31267113 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide variants (SNVs)
Number of subjects: 280000
Study 27651026 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.5, 1, and 3 μg/kg)
Number of subjects: 11
Study 27651026 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine plus milnacipran (25 and 50 mg)
Number of subjects: 11
Study 27651026 — intervention group
Group type: COMPARATOR
Intervention: Milnacipran (25 or 50 mg)
Number of subjects: 11
Study 27651026 — intervention group
Group type: COMPARATOR
Intervention: Milnacipran (50 mg)
Number of subjects: 11
Study 25322262 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance training (50min, moderate intensity, twice a week for 6 weeks)
Number of subjects: 49
Study 25322262 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activities (Control group)
Number of subjects: 49
Study 24346592 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 61
Study 24346592 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical corpectomy and fusion (ACCF)
Number of subjects: 61
Study 22749178 — intervention group
Group type: EXPERIMENTAL
Intervention: 379 mg of Green Tea Extract (GTE)
Number of subjects: 56
Study 19339758 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task cognitive-motor intervention (CGI)
Number of subjects: 13
Study 19339758 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (walking with simple music)
Number of subjects: 13
Study 17728106 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 86
Study 17728106 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 86
Study 15850857 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted education and free testing delivered by a Native Hawaiian physician and CRC survivor, including FOBT demo and multiple reminder calls.
Number of subjects: 121
Study 15850857 — intervention group
Group type: COMPARATOR
Intervention: Culturally targeted presentation, free FOBT, and reminder call delivered by a non-Hawaiian nurse.
Number of subjects: 121
Study 15850857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms received similar and significant gains in CRC knowledge, attitudes, intent, and self-efficacy.
Number of subjects: 121
Study 12539939 — intervention group
Group type: EXPERIMENTAL
Intervention: Steel reconstruction plates
Number of subjects: 14
Study 12539939 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbert cannulated bone screw
Number of subjects: 14
Study 12539939 — intervention group
Group type: COMPARATOR
Intervention: Control group (clavicles without osteosynthesis material)
Number of subjects: 14
Study 10223941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg oral dose following a high-fat breakfast
Number of subjects: 16
Study 10223941 — intervention group
Group type: COMPARATOR
Intervention: Rifapentine 600 mg oral dose during fasting
Number of subjects: 16
Study 10223941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine with high-fat breakfast
Number of subjects: 16
Study 10223941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine
Number of subjects: 16
Study 8582465 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg metoprolol plus 20 mg denopamine
Number of subjects: 10
Study 8582465 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg metoprolol plus denopamine placebo
Number of subjects: 10
Study 8582465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2151407 — intervention group
Group type: EXPERIMENTAL
Intervention: AH23848 70 mg
Number of subjects: 30
Study 2151407 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 300 mg plus dipyridamole 75 mg
Number of subjects: 30
Study 2151407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 386063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 22
Study 386063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31634518 — intervention group
Group type: EXPERIMENTAL
Intervention: Social inclusion (acceptance) condition
Number of subjects: 80
Study 31634518 — intervention group
Group type: COMPARATOR
Intervention: Social exclusion (rejection) condition
Number of subjects: 80
Study 31634518 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal acceptance-rejection perceptions
Number of subjects: 80
Study 31634518 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers' use of food to regulate children's distress
Number of subjects: 80
Study 31634518 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's own BMI
Number of subjects: 80
Study 29563108 — intervention group
Group type: EXPERIMENTAL
Intervention: blisibimod (200 mg weekly)
Number of subjects: 442
Study 29563108 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 442
Study 26893497 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide + Metoprolol (n = 80)
Number of subjects: 173
Study 26893497 — intervention group
Group type: COMPARATOR
Intervention: Flecainide only (n = 72)
Number of subjects: 173
Study 26893497 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol only (n = 21)
Number of subjects: 173
Study 24448756 — intervention group
Group type: EXPERIMENTAL
Intervention: Aranesp (Q weekly or Q 2 weeks)
Number of subjects: 139
Study 24448756 — intervention group
Group type: COMPARATOR
Intervention: Eprex (Q TIW or BIW)
Number of subjects: 139
Study 23090813 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg Methylphenidate (MPH)
Number of subjects: 1
Study 23090813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 20712264 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol plus folic acid plus melatonin (group A)
Number of subjects: 65
Study 20712264 — intervention group
Group type: COMPARATOR
Intervention: myo-inositol plus folic acid (group B)
Number of subjects: 65
Study 18408527 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for psychotic depression
Number of subjects: 118
Study 18408527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative olanzapine dose
Number of subjects: 118
Study 18408527 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week trial completers
Number of subjects: 118
Study 15842259 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD) with PLA/PGA copolymer graft
Number of subjects: 32
Study 15842259 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 32
Study 12455799 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional peritoneal cytologic evaluation
Number of subjects: 108
Study 10513763 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-ended questionnaire format
Number of subjects: 1007
Study 10513763 — intervention group
Group type: COMPARATOR
Intervention: Open-ended questionnaire format
Number of subjects: 1007
Study 9111711 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 33
Study 9111711 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 33
Study 1749203 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg b.i.d.)
Number of subjects: 27
Study 1749203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg b.i.d.)
Number of subjects: 27
Study 1749203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (atenolol and nifedipine)
Number of subjects: 27
Study 1749203 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 27
Study 1749203 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 27
Study 1749203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 27
Study 6810863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate (SCG)
Number of subjects: 26
Study 6810863 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SCG and theophylline
Number of subjects: 26
Study 6810863 — intervention group
Group type: COMPARATOR
Intervention: Oral theophylline
Number of subjects: 26
Study 31349978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Dodecafluoropentane emulsion (DDFPe)
Number of subjects: 24
Study 31349978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose DDFPe
Number of subjects: 24
Study 31349978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28324038 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide plus pioglitazone (combination therapy)
Number of subjects: 101
Study 28324038 — intervention group
Group type: COMPARATOR
Intervention: Basal plus prandial insulin (insulin therapy)
Number of subjects: 101
Study 25400263 — intervention group
Group type: EXPERIMENTAL
Intervention: Running suture technique
Number of subjects: 60
Study 25400263 — intervention group
Group type: COMPARATOR
Intervention: Standard interrupted suture technique
Number of subjects: 60
Study 24792107 — intervention group
Group type: EXPERIMENTAL
Intervention: IntraLASE FS60 laser (IL)
Number of subjects: 40
Study 24792107 — intervention group
Group type: COMPARATOR
Intervention: WaveLight FS200 laser (FS)
Number of subjects: 40
Study 21594619 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (100 mg oral twice daily)
Number of subjects: 70
Study 21594619 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (1,250 mg/m² oral twice daily)
Number of subjects: 70
Study 19349375 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (3 doses of 250 mg/kg per dose, 1 mL/kg per dose, 24 hours apart)
Number of subjects: 40
Study 19349375 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (3 doses of 1 mL/kg per dose, 24 hours apart)
Number of subjects: 40
Study 19349375 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 40
Study 19349375 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 40
Study 17224418 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy (Pm ON)
Number of subjects: 710
Study 17224418 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (Pm OFF)
Number of subjects: 710
Study 14684561 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase (2.5 mg/day)
Number of subjects: 105
Study 14684561 — intervention group
Group type: COMPARATOR
Intervention: No rhDNase (control group)
Number of subjects: 105
Study 12162793 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5-20 mg
Number of subjects: 1026
Study 12162793 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5, 7.5, and 20 mg
Number of subjects: 1026
Study 12162793 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg QD
Number of subjects: 1026
Study 12162793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1026
Study 9839823 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 150 mg + morphine 4 mg
Number of subjects: 60
Study 9839823 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 150 mg + morphine 4 mg + methylprednisolone 40 mg
Number of subjects: 60
Study 9839823 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 60
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC + continuous oral 5-FU (Group A)
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC + continuous oral UFT (Group B)
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MF + UFT (Group C)
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC + continuous oral 5-FU (Group A) at CAD
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC + continuous oral UFT (Group B) at CAD
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MF + UFT (Group C) at CAD
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC + continuous oral 5-FU (Group A) at CIH
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MF + UFT (Group C) at ACC
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC + continuous oral UFT (Group B) at NCC
Number of subjects: 466
Study 7666668 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rate of patients with S2 (serosal exposure), 8 cm < and N0-1 cancer at CIH
Number of subjects: 466
Study 3392363 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate aerosol (GA) 240 micrograms
Number of subjects: 20
Study 3392363 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate aerosol (GA) 480 micrograms
Number of subjects: 20
Study 3392363 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate aerosol (GA) 960 micrograms
Number of subjects: 20
Study 3392363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31821993 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-LOW (40% of arterial occlusion pressure)
Number of subjects: 9
Study 31821993 — intervention group
Group type: EXPERIMENTAL
Intervention: PRACTICAL-LOW (30% of 1-RM)
Number of subjects: 9
Study 31821993 — intervention group
Group type: EXPERIMENTAL
Intervention: PRACTICAL-HIGH (elastic knee wraps stretched to 85% of thigh circumference)
Number of subjects: 9
Study 31821993 — intervention group
Group type: COMPARATOR
Intervention: HL (70% 1-RM)
Number of subjects: 9
Study 30608570 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol interventions
Number of subjects: 836
Study 30608570 — intervention group
Group type: COMPARATOR
Intervention: No/Low blackouts (n = 248; 29.7%)
Number of subjects: 836
Study 30608570 — intervention group
Group type: COMPARATOR
Intervention: High blackouts (n = 159; 19.0%)
Number of subjects: 836
Study 30608570 — intervention group
Group type: COMPARATOR
Intervention: Moderate blackouts (n = 337; 40.3%)
Number of subjects: 836
Study 28500416 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI breakfast followed by 2 min activity breaks every 20 min (HGI-ACT)
Number of subjects: 14
Study 28500416 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI breakfast followed by 2 min activity breaks every 20 min (LGI-ACT)
Number of subjects: 14
Study 28500416 — intervention group
Group type: COMPARATOR
Intervention: High GI breakfast followed by uninterrupted sitting (HGI-SIT)
Number of subjects: 14
Study 28500416 — intervention group
Group type: COMPARATOR
Intervention: Low GI breakfast followed by uninterrupted sitting (LGI-SIT)
Number of subjects: 14
Study 25559495 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitiered oral health educational program for care staff
Number of subjects: 76
Study 25559495 — intervention group
Group type: COMPARATOR
Intervention: No training for care staff (Control)
Number of subjects: 76
Study 23242583 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentum-preserving gastrectomy
Number of subjects: 250
Study 23242583 — intervention group
Group type: COMPARATOR
Intervention: Complete removal of the omentum
Number of subjects: 250
Study 17098159 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 0
Study 12663595 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise consultation
Number of subjects: 70
Study 12663595 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 10367608 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (daytime)
Number of subjects: 15
Study 10367608 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (nighttime)
Number of subjects: 15
Study 10367608 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (24-hour mean)
Number of subjects: 15
Study 10367608 — intervention group
Group type: EXPERIMENTAL
Intervention: LH pulse frequency
Number of subjects: 15
Study 8665335 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (10‐30 mg four times a day)
Number of subjects: 12
Study 8665335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four times a day)
Number of subjects: 12
Study 8665335 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate cessation
Number of subjects: 12
Study 2005708 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms desmopressin spray
Number of subjects: 52
Study 2005708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 2005708 — intervention group
Group type: EXPERIMENTAL
Intervention: 20, 30, and 40 micrograms desmopressin
Number of subjects: 52
Study 6364441 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg loading dose followed by 5.6 mg/h continuous infusion from midnight until 10 am)
Number of subjects: 6
Study 6364441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31318492 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (PA)
Number of subjects: 227
Study 31318492 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps per day
Number of subjects: 227
Study 31318492 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 227